Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of ...
06:27 EDT 9 Sep 2012 | LaMerie
- Combined safety and tolerability data from multiple clinical trials highlight the promising safety profile of solithromycin -
- Population PK, PK-PD target attainment analyses will be used to support intravenous dose selection for planned IV-to-oral Phase 3 trials -
- Additional anti-microbial activity data highlight solithromycin's activity against N. gonorrhoeae and T. pallidum strains
Original Article: Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of ...
More From BioPortfolio on "Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of ..."
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
